5 O
WARNINGS O
AND O
PRECAUTIONS O
EXCERPT O
: O
* O
Elimination O
of O
AUBAGIO O
can O
be O
accelerated O
by O
administration O
of O
cholestyramine O
or O
activated O
charcoal O
for O
11 O
days O
( O
5.3 O
) O
* O
AUBAGIO O
may O
decrease O
WBC O
. O

A O
recent O
CBC O
should O
be O
available O
before O
starting O
AUBAGIO O
. O

Monitor O
for O
signs O
and O
symptoms O
of O
infection O
. O

Consider O
suspending O
treatment O
with O
AUBAGIO O
in O
case O
of O
serious O
infection O
. O

Do O
not O
start O
AUBAGIO O
in O
patients O
with O
active O
infections O
( O
5.4 O
) O
* O
If O
patient O
develops O
symptoms O
consistent O
with O
peripheral O
neuropathy O
, O
evaluate O
patient O
and O
consider O
discontinuing O
AUBAGIO O
( O
5.5 O
) O
* O
Stop O
AUBAGIO O
if O
patient O
develops O
Stevens-Johnson O
syndrome O
or O
toxic O
epidermal O
necrolysis O
( O
5.6 O
) O
* O
AUBAGIO O
may O
increase O
blood O
pressure O
. O

Measure O
blood O
pressure O
at O
treatment O
initiation O
and O
monitor O
blood O
pressure O
during O
treatment O
( O
5.7 O
) O
5.1 O
Hepatotoxicity O
Severe O
liver B-OSE_Labeled_AE
injury I-OSE_Labeled_AE
including O
fatal O
liver B-OSE_Labeled_AE
failure I-OSE_Labeled_AE
and O
dysfunction O
has O
been O
reported O
in O
some O
patients O
treated O
with O
leflunomide O
, O
which O
is O
indicated O
for O
rheumatoid B-Not_AE_Candidate
arthritis I-Not_AE_Candidate
. O

A O
similar O
risk O
would O
be O
expected O
for O
teriflunomide O
because O
recommended O
doses O
of O
teriflunomide O
and O
leflunomide O
result O
in O
a O
similar O
range O
of O
plasma O
concentrations O
of O
teriflunomide O
. O

Patients O
with O
pre-existing O
liver B-Not_AE_Candidate
disease I-Not_AE_Candidate
may O
be O
at O
increased O
risk O
of O
developing O
elevated B-OSE_Labeled_AE
serum I-OSE_Labeled_AE
transaminases I-OSE_Labeled_AE
when O
taking O
AUBAGIO O
. O

Patients O
with O
pre-existing O
acute B-Not_AE_Candidate
or I-Not_AE_Candidate
chronic I-Not_AE_Candidate
liver I-Not_AE_Candidate
disease I-Not_AE_Candidate
, O
or O
those O
with O
serum B-Not_AE_Candidate
alanine I-Not_AE_Candidate
aminotransferase I-Not_AE_Candidate
( I-Not_AE_Candidate
ALT I-Not_AE_Candidate
) I-Not_AE_Candidate
greater I-Not_AE_Candidate
than I-Not_AE_Candidate
two I-Not_AE_Candidate
times I-Not_AE_Candidate
the I-Not_AE_Candidate
upper I-Not_AE_Candidate
limit I-Not_AE_Candidate
of I-Not_AE_Candidate
normal I-Not_AE_Candidate
( I-Not_AE_Candidate
ULN I-Not_AE_Candidate
) O
before O
initiating O
treatment O
, O
should O
not O
normally O
be O
treated O
with O
AUBAGIO O
. O

AUBAGIO O
is O
contraindicated O
in O
patients O
with O
severe O
hepatic B-Not_AE_Candidate
impairment I-Not_AE_Candidate
[ O
see O
Contraindications O
( O
4.1 O
) O
] O
. O

In O
placebo-controlled O
trials O
, O
ALT B-OSE_Labeled_AE
greater I-OSE_Labeled_AE
than I-OSE_Labeled_AE
three I-OSE_Labeled_AE
times I-OSE_Labeled_AE
the I-OSE_Labeled_AE
ULN I-OSE_Labeled_AE
occurred O
in O
61/1045 O
( O
5.8 O
% O
) O
and O
62/1002 O
( O
6.2 O
% O
) O
of O
patients O
receiving O
AUBAGIO O
7 O
mg O
and O
14 O
mg O
, O
respectively O
, O
and O
38/997 O
( O
3.8 O
% O
) O
of O
patients O
receiving O
placebo O
, O
during O
the O
treatment O
period O
. O

These O
elevations O
occurred O
mostly O
within O
the O
first O
year O
of O
treatment O
. O

Half O
of O
the O
cases O
returned O
to O
normal O
without O
drug O
discontinuation O
. O

In O
clinical O
trials O
, O
if O
ALT B-NonOSE_AE
elevation I-NonOSE_AE
was O
greater O
than O
three O
times O
the O
ULN O
on O
two O
consecutive O
tests O
, O
AUBAGIO O
was O
discontinued O
and O
patients O
underwent O
an O
accelerated O
elimination O
procedure O
[ O
see O
Warnings O
and O
Precautions O
( O
5.3 O
) O
] O
. O

Of O
the O
patients O
who O
underwent O
discontinuation O
and O
accelerated O
elimination O
in O
controlled O
trials O
, O
half O
returned O
to O
normal O
or O
near O
normal O
values O
within O
2 O
months O
. O

One O
patient O
in O
the O
controlled O
trials O
developed O
ALT B-OSE_Labeled_AE
3 I-OSE_Labeled_AE
2 I-OSE_Labeled_AE
times I-OSE_Labeled_AE
the I-OSE_Labeled_AE
ULN I-OSE_Labeled_AE
and O
jaundice B-OSE_Labeled_AE
5 O
months O
after O
initiation O
of O
AUBAGIO O
14 O
mg O
treatment O
. O

The O
patient O
was O
hospitalized O
for O
5 O
weeks O
and O
recovered O
after O
plasmapheresis O
and O
cholestyramine O
accelerated O
elimination O
procedure O
. O

AUBAGIO B-NonOSE_AE
- I-NonOSE_AE
induced I-NonOSE_AE
liver I-NonOSE_AE
injury I-NonOSE_AE
in O
this O
patient O
could O
not O
be O
ruled O
out O
. O

Obtain O
serum O
transaminase O
and O
bilirubin O
levels O
within O
6 O
months O
before O
initiation O
of O
AUBAGIO O
therapy O
. O

Monitor O
ALT O
levels O
at O
least O
monthly O
for O
six O
months O
after O
starting O
AUBAGIO O
. O

Consider O
additional O
monitoring O
when O
AUBAGIO O
is O
given O
with O
other O
potentially O
hepatotoxic B-NonOSE_AE
drugs I-NonOSE_AE
. O

Consider O
discontinuing O
AUBAGIO O
if O
serum O
transaminase B-NonOSE_AE
increase I-NonOSE_AE
( O
greater O
than O
three O
times O
the O
ULN O
) O
is O
confirmed O
. O

Monitor O
serum O
transaminase O
and O
bilirubin O
on O
AUBAGIO O
therapy O
, O
particularly O
in O
patients O
who O
develop O
symptoms O
suggestive O
of O
hepatic B-NonOSE_AE
dysfunction I-NonOSE_AE
, O
such O
as O
unexplained O
nausea B-NonOSE_AE
, O
vomiting B-NonOSE_AE
, O
abdominal B-NonOSE_AE
pain I-NonOSE_AE
, O
fatigue B-NonOSE_AE
, O
anorexia B-NonOSE_AE
, O
or O
jaundice B-NonOSE_AE
and/or O
dark B-NonOSE_AE
urine I-NonOSE_AE
. O

If O
liver B-NonOSE_AE
injury I-NonOSE_AE
is O
suspected O
to O
be O
AUBAGIO-induced O
, O
discontinue O
AUBAGIO O
and O
start O
an O
accelerated O
elimination O
procedure O
[ O
see O
Warnings O
and O
Precautions O
( O
5.3 O
) O
] O
and O
monitor O
liver O
tests O
weekly O
until O
normalized O
. O

If O
AUBAGIO B-NonOSE_AE
- I-NonOSE_AE
induced I-NonOSE_AE
liver I-NonOSE_AE
injury I-NonOSE_AE
is O
unlikely O
because O
some O
other O
probable O
cause O
has O
been O
found O
, O
resumption O
of O
AUBAGIO O
therapy O
may O
be O
considered O
. O

5.2 O
Use O
in O
Women O
of O
Childbearing O
Potential O
There O
are O
no O
adequate O
and O
well-controlled O
studies O
evaluating O
AUBAGIO O
in O
pregnant B-Not_AE_Candidate
women O
. O

However O
, O
based O
on O
animal O
studies O
, O
teriflunomide O
may O
increase B-OSE_Labeled_AE
the I-OSE_Labeled_AE
risk I-OSE_Labeled_AE
of I-OSE_Labeled_AE
teratogenic I-OSE_Labeled_AE
effects I-OSE_Labeled_AE
or O
fetal B-NonOSE_AE
death I-NonOSE_AE
when O
administered O
to O
a O
pregnant B-Not_AE_Candidate
woman O
[ O
see O
Contraindications O
( O
4.2 O
) O
] O
. O

Women O
of O
childbearing O
potential O
must O
not O
be O
started O
on O
AUBAGIO O
until O
pregnancy B-Not_AE_Candidate
is O
excluded O
and O
it O
has O
been O
confirmed O
that O
they O
are O
using O
reliable O
contraception O
. O

Before O
starting O
treatment O
with O
AUBAGIO O
, O
patients O
must O
be O
fully O
counseled O
on O
the O
potential O
for O
serious O
risk O
to O
the O
fetus O
. O

The O
patient O
must O
be O
advised O
that O
if O
there O
is O
any O
delay O
in O
onset O
of O
menses O
or O
any O
other O
reason O
to O
suspect O
pregnancy B-NonOSE_AE
, O
they O
must O
notify O
the O
physician O
immediately O
for O
pregnancy O
testing O
and O
, O
if O
positive O
, O
the O
physician O
and O
patient O
must O
discuss O
the O
risk O
to O
the O
fetus O
. O

It O
is O
possible O
that O
rapidly O
lowering O
the O
plasma O
concentration O
of O
teriflunomide O
by O
instituting O
an O
accelerated O
elimination O
procedure O
may O
decrease O
the O
risk O
to O
the O
fetus O
from O
AUBAGIO O
[ O
see O
Warnings O
and O
Precautions O
( O
5.3 O
) O
] O
. O

Upon O
discontinuing O
AUBAGIO O
, O
it O
is O
recommended O
that O
all O
women O
of O
childbearing O
potential O
undergo O
an O
accelerated O
elimination O
procedure O
. O

Women O
receiving O
AUBAGIO O
treatment O
who O
wish O
to O
become O
pregnant B-NonOSE_AE
must O
discontinue O
AUBAGIO O
and O
undergo O
an O
accelerated O
elimination O
procedure O
, O
which O
includes O
verification O
of O
teriflunomide O
plasma O
concentrations O
less O
than O
0.02 O
mg/L O
( O
0.02 O
mcg/mL O
) O
. O

Human O
plasma O
concentrations O
of O
teriflunomide O
less O
than O
0.02 O
mg/L O
( O
0.02 O
mcg/mL O
) O
are O
expected O
to O
have O
minimal O
risk O
[ O
see O
Contraindications O
( O
4.2 O
) O
, O
Warnings O
and O
Precautions O
( O
5.3 O
) O
and O
Use O
in O
Specific O
Populations O
( O
8.1 O
) O
] O
. O

5.3 O
Procedure O
for O
Accelerated O
Elimination O
of O
Teriflunomide O
Teriflunomide O
is O
eliminated O
slowly O
from O
the O
plasma O
. O

Without O
an O
accelerated O
elimination O
procedure O
, O
it O
takes O
on O
average O
8 O
months O
to O
reach O
plasma O
concentrations O
less O
than O
0.02 O
mg/L O
, O
although O
because O
of O
individual O
variations O
in O
drug O
clearance O
it O
may O
take O
as O
long O
as O
2 O
years O
. O

An O
accelerated O
elimination O
procedure O
could O
be O
used O
at O
any O
time O
after O
discontinuation O
of O
AUBAGIO O
. O

Elimination O
can O
be O
accelerated O
by O
either O
of O
the O
following O
procedures O
: O
* O
Administration O
of O
cholestyramine O
8 O
g O
every O
8 O
hours O
for O
11 O
days O
. O

If O
cholestyramine O
8 O
g O
three O
times O
a O
day O
is O
not O
well O
tolerated O
, O
cholestyramine O
4 O
g O
three O
times O
a O
day O
can O
be O
used O
. O

* O
Administration O
of O
50 O
g O
oral O
activated O
charcoal O
powder O
every O
12 O
hours O
for O
11 O
days O
. O

If O
either O
elimination O
procedure O
is O
poorly O
tolerated O
, O
treatment O
days O
do O
not O
need O
to O
be O
consecutive O
unless O
there O
is O
a O
need O
to O
lower O
teriflunomide O
plasma O
concentration O
rapidly O
. O

At O
the O
end O
of O
11 O
days O
, O
both O
regimens O
successfully O
accelerated O
teriflunomide O
elimination O
, O
leading O
to O
more O
than O
98 O
% O
decrease O
in O
teriflunomide O
plasma O
concentrations O
. O

Use O
of O
the O
accelerated O
elimination O
procedure O
may O
potentially O
result O
in O
return O
of O
disease O
activity O
if O
the O
patient O
had O
been O
responding O
to O
AUBAGIO O
treatment O
. O

5.4 O
Bone O
Marrow O
Effects/Immunosuppression O
Potential/Infections O
White O
Blood O
Cell O
( O
WBC O
) O
count O
decrease O
A O
mean O
decrease B-OSE_Labeled_AE
in I-OSE_Labeled_AE
white I-OSE_Labeled_AE
blood I-OSE_Labeled_AE
cell I-OSE_Labeled_AE
( I-OSE_Labeled_AE
WBC I-OSE_Labeled_AE
) O
count O
of O
approximately O
15 O
% O
( O
mainly O
neutrophils O
and O
lymphocytes O
) O
and O
in O
platelet O
count O
of O
approximately O
10 O
% O
was O
observed O
in O
placebo-controlled O
trials O
with O
7 O
mg O
and O
14 O
mg O
of O
AUBAGIO O
compared O
to O
baseline O
. O

The O
decrease B-OSE_Labeled_AE
in I-OSE_Labeled_AE
mean I-OSE_Labeled_AE
WBC I-OSE_Labeled_AE
count I-OSE_Labeled_AE
occurred O
during O
the O
first O
6 O
weeks O
and O
WBC O
count O
remained O
low O
during O
treatment O
. O

In O
placebo-controlled O
studies O
, O
neutrophil B-OSE_Labeled_AE
count I-OSE_Labeled_AE
< I-OSE_Labeled_AE
1 I-OSE_Labeled_AE
. I-OSE_Labeled_AE
5 I-OSE_Labeled_AE
* I-OSE_Labeled_AE
1 I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
9 I-OSE_Labeled_AE
/ I-OSE_Labeled_AE
L I-OSE_Labeled_AE
was O
observed O
in O
12 O
% O
and O
16 O
% O
of O
patients O
receiving O
AUBAGIO O
7 O
mg O
and O
14 O
mg O
, O
respectively O
, O
compared O
with O
7 O
% O
of O
patients O
receiving O
placebo O
; O
lymphocyte B-OSE_Labeled_AE
count I-OSE_Labeled_AE
< I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
. I-OSE_Labeled_AE
8 I-OSE_Labeled_AE
* I-OSE_Labeled_AE
1 I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
9 I-OSE_Labeled_AE
/ I-OSE_Labeled_AE
L I-OSE_Labeled_AE
was O
observed O
in O
10 O
% O
and O
12 O
% O
of O
patients O
receiving O
AUBAGIO O
7 O
mg O
and O
14 O
mg O
, O
respectively O
, O
compared O
with O
6 O
% O
of O
patients O
receiving O
placebo O
. O

No O
cases O
of O
serious O
pancytopenia B-NonOSE_AE
were O
reported O
in O
premarketing O
clinical O
trials O
of O
AUBAGIO O
but O
rare O
cases O
of O
pancytopenia B-OSE_Labeled_AE
, O
agranulocytosis B-OSE_Labeled_AE
, O
and O
thrombocytopenia B-OSE_Labeled_AE
have O
been O
reported O
in O
the O
postmarketing O
setting O
with O
leflunomide O
. O

A O
similar O
risk O
would O
be O
expected O
for O
AUBAGIO O
[ O
see O
Clinical O
Pharmacology O
( O
12.3 O
) O
] O
. O

Obtain O
a O
complete O
blood O
cell O
count O
( O
CBC O
) O
within O
6 O
months O
before O
the O
initiation O
of O
treatment O
with O
AUBAGIO O
. O

Further O
monitoring O
should O
be O
based O
on O
signs O
and O
symptoms O
suggestive O
of O
bone B-NonOSE_AE
marrow I-NonOSE_AE
suppression I-NonOSE_AE
. O

Risk O
of O
Infection O
/ O
Tuberculosis O
Screening O
Patients O
with O
active O
acute B-Not_AE_Candidate
or O
chronic O
infections I-Not_AE_Candidate
should O
not O
start O
treatment O
until O
the O
infection O
( O
s O
) O
is O
resolved O
. O

If O
a O
patient O
develops O
a O
serious O
infection B-NonOSE_AE
consider O
suspending O
treatment O
with O
AUBAGIO O
and O
using O
an O
accelerated O
elimination O
procedure O
. O

Reassess O
the O
benefits O
and O
risks O
prior O
to O
resumption O
of O
therapy O
. O

Instruct O
patients O
receiving O
AUBAGIO O
to O
report O
symptoms O
of O
infections B-NonOSE_AE
to O
a O
physician O
. O

AUBAGIO O
is O
not O
recommended O
for O
patients O
with O
severe O
immunodeficiency B-Not_AE_Candidate
, O
bone B-Not_AE_Candidate
marrow I-Not_AE_Candidate
disease I-Not_AE_Candidate
, O
or O
severe O
, O
uncontrolled O
infections B-Not_AE_Candidate
. O

Medications O
like O
AUBAGIO O
that O
have O
immunosuppression B-OSE_Labeled_AE
potential O
may O
cause O
patients O
to O
be O
more B-NonOSE_AE
susceptible I-NonOSE_AE
to I-NonOSE_AE
infections I-NonOSE_AE
, O
including O
opportunistic B-NonOSE_AE
infections I-NonOSE_AE
. O

In O
placebo-controlled O
studies O
of O
AUBAGIO O
, O
no O
overall O
increase O
in O
the O
risk O
of O
serious O
infections B-NonOSE_AE
was O
observed O
with O
AUBAGIO O
7 O
mg O
( O
2.2 O
% O
) O
or O
14 O
mg O
( O
2.7 O
% O
) O
compared O
to O
placebo O
( O
2.2 O
% O
) O
. O

However O
, O
one O
fatal O
case O
of O
klebsiella B-OSE_Labeled_AE
pneumonia I-OSE_Labeled_AE
sepsis I-OSE_Labeled_AE
occurred O
in O
a O
patient O
taking O
AUBAGIO O
14 O
mg O
for O
1.7 O
years O
. O

Fatal O
infections B-OSE_Labeled_AE
have O
been O
reported O
in O
the O
post-marketing O
setting O
in O
patients O
receiving O
leflunomide O
, O
especially O
Pneumocystis B-OSE_Labeled_AE
jiroveci I-OSE_Labeled_AE
pneumonia I-OSE_Labeled_AE
and O
aspergillosis B-OSE_Labeled_AE
. O

Most O
of O
the O
reports O
were O
confounded O
by O
concomitant O
immunosuppressant O
therapy O
and/or O
comorbid O
illness O
which O
, O
in O
addition O
to O
rheumatoid B-Not_AE_Candidate
disease I-Not_AE_Candidate
, O
may O
predispose O
patients O
to O
infection B-NonOSE_AE
. O

In O
clinical O
studies O
with O
AUBAGIO O
, O
cytomegalovirus B-OSE_Labeled_AE
hepatitis I-OSE_Labeled_AE
reactivation I-OSE_Labeled_AE
has O
been O
observed O
. O

In O
clinical O
studies O
with O
AUBAGIO O
, O
cases O
of O
tuberculosis B-OSE_Labeled_AE
have O
been O
observed O
. O

Prior O
to O
initiating O
AUBAGIO O
, O
screen O
patients O
for O
latent B-Not_AE_Candidate
tuberculosis I-Not_AE_Candidate
infection I-Not_AE_Candidate
with O
a O
tuberculin O
skin O
test O
or O
with O
a O
blood O
test O
for O
mycobacterium B-Not_AE_Candidate
tuberculosis I-Not_AE_Candidate
infection I-Not_AE_Candidate
. O

AUBAGIO O
has O
not O
been O
studied O
in O
patients O
with O
a O
positive B-Not_AE_Candidate
tuberculosis I-Not_AE_Candidate
screen I-Not_AE_Candidate
, O
and O
the O
safety O
of O
AUBAGIO O
in O
individuals O
with O
latent B-Not_AE_Candidate
tuberculosis I-Not_AE_Candidate
infection I-Not_AE_Candidate
is O
unknown O
. O

For O
patients O
testing B-Not_AE_Candidate
positive I-Not_AE_Candidate
in I-Not_AE_Candidate
tuberculosis I-Not_AE_Candidate
screening I-Not_AE_Candidate
, O
treat O
by O
standard O
medical O
practice O
prior O
to O
therapy O
with O
AUBAGIO O
. O

Vaccination O
No O
clinical O
data O
are O
available O
on O
the O
efficacy O
and O
safety O
of O
live O
vaccinations O
in O
patients O
taking O
AUBAGIO O
. O

Vaccination O
with O
live O
vaccines O
is O
not O
recommended O
. O

The O
long O
half-life O
of O
AUBAGIO O
should O
be O
considered O
when O
contemplating O
administration O
of O
a O
live O
vaccine O
after O
stopping O
AUBAGIO O
. O

Malignancy O
The O
risk O
of O
malignancy B-OSE_Labeled_AE
, O
particularly O
lymphoproliferative B-OSE_Labeled_AE
disorders I-OSE_Labeled_AE
, O
is O
increased O
with O
the O
use O
of O
some O
immunosuppressive B-NonOSE_AE
medications O
. O

There O
is O
a O
potential O
for O
immunosuppression B-OSE_Labeled_AE
with O
AUBAGIO O
. O

No O
apparent O
increase O
in O
the O
incidence O
of O
malignancies B-NonOSE_AE
and O
lymphoproliferative B-NonOSE_AE
disorders I-NonOSE_AE
was O
reported O
in O
the O
AUBAGIO O
clinical O
trials O
, O
but O
larger O
and O
longer-term O
studies O
would O
be O
needed O
to O
determine O
whether O
there O
is O
an O
increased O
risk O
of O
malignancy B-NonOSE_AE
or O
lymphoproliferative B-NonOSE_AE
disorders I-NonOSE_AE
with O
AUBAGIO O
. O

5.5 O
Peripheral O
Neuropathy O
In O
placebo-controlled O
studies O
, O
peripheral B-OSE_Labeled_AE
neuropathy I-OSE_Labeled_AE
, O
including O
both O
polyneuropathy B-OSE_Labeled_AE
and O
mononeuropathy B-OSE_Labeled_AE
( O
e.g. O
, O
carpal B-OSE_Labeled_AE
tunnel I-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
) O
, O
occurred O
more O
frequently O
in O
patients O
taking O
AUBAGIO O
than O
in O
patients O
taking O
placebo O
. O

The O
incidence O
of O
peripheral B-OSE_Labeled_AE
neuropathy I-OSE_Labeled_AE
confirmed O
by O
nerve O
conduction O
studies O
was O
1.4 O
% O
( O
13 O
patients O
) O
and O
1.9 O
% O
( O
17 O
patients O
) O
of O
patients O
receiving O
7 O
mg O
and O
14 O
mg O
of O
AUBAGIO O
, O
respectively O
, O
compared O
with O
0.4 O
% O
receiving O
placebo O
( O
4 O
patients O
) O
. O

Treatment O
was O
discontinued O
in O
0.7 O
% O
( O
8 O
patients O
) O
with O
confirmed O
peripheral B-OSE_Labeled_AE
neuropathy I-OSE_Labeled_AE
( O
3 O
patients O
receiving O
AUBAGIO O
7 O
mg O
and O
5 O
patients O
receiving O
AUBAGIO O
14 O
mg O
) O
. O

Five O
of O
them O
recovered O
following O
treatment O
discontinuation O
. O

Not O
all O
cases O
of O
peripheral B-OSE_Labeled_AE
neuropathy I-OSE_Labeled_AE
resolved O
with O
continued O
treatment O
. O

Peripheral B-OSE_Labeled_AE
neuropathy I-OSE_Labeled_AE
also O
occurred O
in O
patients O
receiving O
leflunomide O
. O

Age O
older O
than O
60 O
years O
, O
concomitant O
neurotoxic B-NonOSE_AE
medications I-NonOSE_AE
, O
and O
diabetes B-Not_AE_Candidate
may O
increase O
the O
risk O
for O
peripheral B-NonOSE_AE
neuropathy I-NonOSE_AE
. O

If O
a O
patient O
taking O
AUBAGIO O
develops O
symptoms O
consistent O
with O
peripheral B-NonOSE_AE
neuropathy I-NonOSE_AE
, O
such O
as O
bilateral B-NonOSE_AE
numbness I-NonOSE_AE
or O
tingling O
of I-NonOSE_AE
hands I-NonOSE_AE
or O
feet O
, O
consider O
discontinuing O
AUBAGIO O
therapy O
and O
performing O
an O
accelerated O
elimination O
procedure O
[ O
see O
Warnings O
and O
Precautions O
( O
5.3 O
) O
] O
. O

5.6 O
Skin O
Reactions O
Rare O
cases O
of O
Stevens B-OSE_Labeled_AE
- I-OSE_Labeled_AE
Johnson I-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
and O
toxic B-OSE_Labeled_AE
epidermal I-OSE_Labeled_AE
necrolysis I-OSE_Labeled_AE
have O
been O
reported O
in O
patients O
with O
rheumatoid B-Not_AE_Candidate
arthritis I-Not_AE_Candidate
receiving O
leflunomide O
. O

A O
similar O
risk O
would O
be O
expected O
for O
AUBAGIO O
[ O
see O
Clinical O
Pharmacology O
( O
12.3 O
) O
] O
. O

If O
a O
patient O
taking O
AUBAGIO O
develops O
any O
of O
these O
conditions O
, O
stop O
AUBAGIO O
therapy O
and O
perform O
an O
accelerated O
elimination O
procedure O
[ O
see O
Warnings O
and O
Precautions O
( O
5.3 O
) O
] O
. O

5.7 O
Increased O
Blood O
Pressure O
In O
placebo-controlled O
studies O
, O
the O
mean B-OSE_Labeled_AE
change I-OSE_Labeled_AE
from O
basel O
in I-OSE_Labeled_AE
e O
to O
the O
end O
of O
study O
in O
systolic I-OSE_Labeled_AE
blood I-OSE_Labeled_AE
pressure I-OSE_Labeled_AE
was O
+2.3 O
mmHg O
and O
+2.7 O
mmHg O
for O
AUBAGIO O
7 O
mg O
and O
14 O
mg O
, O
respectively O
, O
and O
-0.6 O
mmHg O
for O
placebo O
. O

The O
change B-OSE_Labeled_AE
from O
basel O
in I-OSE_Labeled_AE
e O
in O
diastolic I-OSE_Labeled_AE
blood I-OSE_Labeled_AE
pressure I-OSE_Labeled_AE
was O
+1.4 O
mmHg O
and O
+1.9 O
mmHg O
for O
AUBAGIO O
7 O
mg O
and O
14 O
mg O
, O
respectively O
, O
and O
-0.3 O
mmHg O
for O
placebo O
. O

Hypertension B-OSE_Labeled_AE
was O
an O
adverse O
reaction O
in O
3.1 O
% O
and O
4.3 O
% O
of O
patients O
treated O
with O
7 O
mg O
or O
14 O
mg O
of O
AUBAGIO O
compared O
with O
1.8 O
% O
for O
placebo O
. O

Check O
blood O
pressure O
before O
start O
of O
AUBAGIO O
treatment O
and O
periodically O
thereafter O
. O

Elevated B-NonOSE_AE
blood I-NonOSE_AE
pressure I-NonOSE_AE
should O
be O
appropriately O
managed O
during O
treatment O
with O
AUBAGIO O
. O

5.8 O
Respiratory B-OSE_Labeled_AE
Effects I-OSE_Labeled_AE
Interstitial B-OSE_Labeled_AE
lung I-OSE_Labeled_AE
disease I-OSE_Labeled_AE
and O
worsening B-OSE_Labeled_AE
of I-OSE_Labeled_AE
pre I-OSE_Labeled_AE
- I-OSE_Labeled_AE
existing I-OSE_Labeled_AE
interstitial I-OSE_Labeled_AE
lung I-OSE_Labeled_AE
disease I-OSE_Labeled_AE
have O
been O
reported O
during O
treatment O
with O
leflunomide O
. O

A O
similar O
risk O
would O
be O
expected O
for O
AUBAGIO O
[ O
see O
Clinical O
Pharmacology O
( O
12.3 O
) O
] O
. O

Interstitial B-NonOSE_AE
lung I-NonOSE_AE
disease I-NonOSE_AE
may O
be O
fatal O
. O

Interstitial B-OSE_Labeled_AE
lung I-OSE_Labeled_AE
disease I-OSE_Labeled_AE
may O
occur O
acutely O
at O
any O
time O
during O
therapy O
and O
has O
a O
variable O
clinical O
presentation O
. O

New O
onset O
or O
worsening B-NonOSE_AE
pulmonary I-NonOSE_AE
symptoms I-NonOSE_AE
, O
such O
as O
cough B-NonOSE_AE
and O
dyspnea B-NonOSE_AE
, O
with O
or O
without O
associated O
fever B-NonOSE_AE
, O
may O
be O
a O
reason O
for O
discontinuation O
of O
the O
therapy O
and O
for O
further O
investigation O
as O
appropriate O
. O

If O
discontinuation O
of O
the O
drug O
is O
necessary O
, O
consider O
initiation O
of O
an O
accelerated O
elimination O
procedure O
[ O
see O
Warnings O
and O
Precautions O
( O
5.3 O
) O
] O
. O

5.9 O
Concomitant O
Use O
with O
Immunosuppressive O
or O
Immunomodulating O
Therapies O
Co-administration O
with O
antineoplastic O
, O
or O
immunosuppressive O
therapies O
used O
for O
treatment O
of O
multiple B-Not_AE_Candidate
sclerosis I-Not_AE_Candidate
has O
not O
been O
evaluated O
. O

Safety O
studies O
in O
which O
AUBAGIO O
was O
concomitantly O
administered O
with O
other O
immune O
modulating O
therapies O
for O
up O
to O
one O
year O
( O
interferon O
beta O
, O
glatiramer O
acetate O
) O
did O
not O
reveal O
any O
specific O
safety O
concerns O
. O

The O
long O
term O
safety O
of O
these O
combinations O
in O
the O
treatment O
of O
multiple B-Not_AE_Candidate
sclerosis I-Not_AE_Candidate
has O
not O
been O
established O
. O

In O
any O
situation O
in O
which O
the O
decision O
is O
made O
to O
switch O
from O
AUBAGIO O
to O
another O
agent O
with O
a O
known O
potential O
for O
hematologic B-NonOSE_AE
suppression I-NonOSE_AE
, O
it O
would O
be O
prudent O
to O
monitor O
for O
hematologic B-NonOSE_AE
toxicity I-NonOSE_AE
, O
because O
there O
will O
be O
overlap O
of O
systemic O
exposure O
to O
both O
compounds O
. O

Use O
of O
an O
accelerated O
elimination O
procedure O
may O
decrease O
this O
risk O
, O
but O
may O
also O
potentially O
result O
in O
return O
of O
disease O
activity O
if O
the O
patient O
had O
been O
responding O
to O
AUBAGIO O
treatment O
[ O
see O
Warnings O
and O
Precautions O
( O
5.3 O
) O
] O
. O

